Product Pipeline

Cardiovascular Disease

Thrombosis plays a major role in the development of cardiovascular disease (CVD), cerebovascular disease (stroke and TIA) and peripheral vascular disease (PVD). CVD accounts for over 72 million doctor visits, over 7 million hospitalizations every year and is the leading cause of death in the US (2,500 per day). There are 700,000 stroke cases per year in the US and over 20.5 million strokes world-wide. Current antiplatelet drugs such as Aspirin (89 million tablets per day in US), Plavix® ($9.6 billion global sales in 2010) and combination therapy have several serious side effects including GI ulceration and bleeding and cerebral bleeding. Additionally, current drugs block only one pathway and 30-40% of patients have recurrent attacks.

Based on Sagene’s preclinical studies, selegiline enhances the antiplatelet properties of Aspirin or Plavix® by targeting multiple pathways (intracellular messengers) of platelet aggregation, preventing and reducing brain damage caused by strokes.